More about

Antifungal Agent

News
July 21, 2021
4 min read
Save

Antifungal stewardship: Core elements to success

Antimicrobial stewardship has been defined as coordinated interventions designed to improve and measure appropriate use of antimicrobial agents by promoting the selection of optimal drug regimens.

News
May 05, 2021
3 min read
Save

Novel antifungal effective against vulvovaginal candidiasis in phase 3 trials

Ibrexafungerp was superior to placebo in patients with vulvovaginal candidiasis, with statistically significant rates of clinical cure, clinical improvement and mycological eradication, according to results of the phase 3 VANISH-306 trial.

News
October 17, 2019
1 min read
Save

Eyevance acquires Tobradex ST, Natacyn

Eyevance Pharmaceuticals has acquired Tobradex ST and Natacyn from Novartis, according to a press release.

News
October 10, 2019
1 min read
Save

Patients overpay more for brand-name topical dermatologic drugs

Among topical dermatologic drugs, the mean overpayment for brand-name drugs was more than double that of generics, based on an analysis of claims data of privately insured individuals published in JAMA Dermatology.

News
October 09, 2019
2 min read
Save

‘Handshake stewardship’ effective and sustainable

Findings from an 8-year retrospective assessment of a handshake stewardship approach implemented at Children’s Hospital Colorado — characterized by team evaluation of prescribed antimicrobials and in-person feedback — showed that it is an effective and sustainable approach for stewardship efforts, researchers reported.

News
September 06, 2019
2 min read
Save

Cell dysregulation may play role in development, exacerbation of head and neck dermatitis

The exacerbation or development of head and neck dermatitis in patients treated for atopic dermatitis with dupilumab may be caused by a dysregulation in the balance of the T helper cell signaling pathway, according to a research letter in JAMA Dermatology.

News
June 12, 2018
2 min watch
Save

VIDEO: New C. auris data ‘helpful’ for clinicians

ATLANTA — In this video, Infectious Disease News Editorial Board member Ellie J.C. Goldstein, MD, discusses an analysis of nearly 700 Candida auris isolates from New York City, which has experienced more cases of the fungal infection than any other state. None of the isolates included in the study were resistant to all three classes of antifungals, and few showed resistance to echinocandins, which are recommended by the CDC as initial therapy to treat C. auris infections.